Skip to main content
. 2023 Nov 28;223(2):e202211026. doi: 10.1083/jcb.202211026

Figure S1.

Figure S1.

Western blots to confirm FzlA levels during strain characterization. (A–F) Western blot analysis using primary antibody recognizing either FzlA (αFzlA) or the loading control MreB (αMreB). (A and B) Overexpression of fzlA variants—WT FzlA (WT), a C-terminal tail mutant (D227K), or a mutant unable to bind FtsZ (NB2)—in WT and ftsW**I* (hyp) backgrounds compared with (EV) controls. (A) Strains with high FzlA were diluted 1:20 before loading as indicated to enable detection of all samples at a single exposure time. (B) Same as A but samples were all undiluted. (C) FzlA is not detected in the ∆fzlA; ftsW**I* strain. (D) fzlA induction in the halo-ftsW background (EG3523) as a function of xylose concentration to match FzlA levels in the WT halo-ftsW (EG3052) background. We selected 0.001% xylose as the closest approximation of WT FzlA levels. (E) FzlA depletion in the halo-ftsW background (EG3523). (F) FzlA overproduction in the halo-ftsW (EG3519) and halo-ftsW**; ftsI* (EG3525) backgrounds, as well as the respective EV controls (WT: EG3537. ftsW**I*: EG3538). Source data are available for this figure: SourceData FS1.